Soliman R, Feid-Allah H M, Mohamed H F
J Pharm Sci. 1981 Aug;70(8):952-6. doi: 10.1002/jps.2600700834.
3-Substituted 5-methyl-1-(p-[(3,5-dimethyl)pyrazol-1-yl]-, 5-methyl-1-(p-[(5-methyl-3-carboxy)pyrazol-1-yl]-, 1-(p-[(3-methyl-5-phenyl)pyrazol-1-yl]-, and 1-(p-[(3-methyl-4-bromo-5-phenyl)pyrazol-1-yl]benzenesulfonyl)-2-thiohydantoin and their 5-methyl-2-thiohydantoin and 5,6-dihydro-4(3H)-oxo-2(1H)-pyrimidinethione derivatives were prepared for evaluation as hypoglycemic agents. Biological testing showed that some of these compounds possessed antidiabetic activity.
制备了3-取代的5-甲基-1-(对-[(3,5-二甲基)吡唑-1-基]、5-甲基-1-(对-[(5-甲基-3-羧基)吡唑-1-基]、1-(对-[(3-甲基-5-苯基)吡唑-1-基]以及1-(对-[(3-甲基-4-溴-5-苯基)吡唑-1-基]苯磺酰基)-2-硫代乙内酰脲及其5-甲基-2-硫代乙内酰脲和5,6-二氢-4(3H)-氧代-2(1H)-嘧啶硫酮衍生物，以评估其作为降血糖剂的性能。生物测试表明，其中一些化合物具有抗糖尿病活性。
